Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics (NQ: CORT )

24.32 -0.15 (-0.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 611,775
Open 24.37
Bid (Size) 23.49 (1)
Ask (Size) 25.00 (1)
Prev. Close 24.47
Today's Range 23.93 - 24.87
52wk Range 17.19 - 30.14
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire

Performance

YTD
+20.58%
+20.58%
1 Month
+20.58%
+20.58%
3 Month
-14.73%
-14.73%
6 Month
-14.15%
-14.15%
1 Year
+26.27%
+26.27%

More News

Read More
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Corcept Therapeutics Return On Capital Employed Overview
Via Benzinga
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
Via Benzinga
Our 7 Top Biotech Stock Picks for 2023
Via InvestorPlace
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
From Corcept Therapeutics Incorporated
Via Globe NewsWire
Corcept Therapeutics Provides Miricorilant Clinical Development Update
From Corcept Therapeutics Incorporated
Via Globe NewsWire
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Globe NewsWire
Corcept Therapeutics's Earnings: A Preview
Via Benzinga
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Globe NewsWire
These 3 Stocks Are Winning the Bear Market -- Here's How
Via The Motley Fool
7 Under-the-Radar Stocks With 100% Upside Potential
Via InvestorPlace
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
From Corcept Therapeutics Incorporated
Via Globe NewsWire
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
Via Investor's Business Daily
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
Via Benzinga
3 Biotech Stocks Outperforming a Bear Market
Via InvestorPlace
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
Via Investor's Business Daily
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%
Via Investor's Business Daily
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating
Via Investor's Business Daily
Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
Via Investor's Business Daily
Kura Oncology Stock Scores Rising Relative Strength
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.